Company intelligence / Profile preview

ArcticZymes Technologies

Ownership: Private
Development stage: Other

Overview

ArcticZymes Technologies has a robust commercial portfolio of specialized enzymes designed for biomanufacturing, molecular diagnostics, gene therapy production, and research. Their salt-active nucleases and heat-labile enzymes are market standards in several workflow steps. The company does not develop therapeutics but supplies critical reagents to the life sciences industry.

Therapeutic areas: Other
Modalities: Recombinant proteinRecombinant proteaseProteinEnzyme replacement therapy (for research/biomanufacturing use)Biologic
Industry: Chemicals & Materials

Partnerships

Not specifically listed; company collaborates with commercial partners via licensing agreements for enzyme supply to biopharma/diagnostics companies.

Beyond the preview

Go deeper on ArcticZymes Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArcticZymes Technologies.

Explore the full profile